Sino Biopharmaceutical Ltd (1177)

Currency in HKD
8.11
+0.37(+4.78%)
Closed·
1177 Scorecard
Full Analysis
Trading at a high earnings multiple
1177 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.708.28
52 wk Range
2.678.46
Key Statistics
Bid/Ask
8.11 / 8.10
Prev. Close
7.69
Open
7.71
Day's Range
7.7-8.28
52 wk Range
2.67-8.46
Volume
151.95M
Average Volume (3m)
185.31M
1-Year Change
144.16%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1177 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.53
Upside
+5.16%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Sino Biopharmaceutical Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Sino Biopharmaceutical Ltd Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Employees
23056
Market
Hong Kong

Compare 1177 to Peers and Sector

Metrics to compare
1177
Peers
Sector
Relationship
P/E Ratio
32.5x18.6x−0.6x
PEG Ratio
−9.17−0.270.00
Price/Book
3.8x1.9x2.6x
Price / LTM Sales
4.1x2.7x3.3x
Upside (Analyst Target)
11.6%14.2%39.1%
Fair Value Upside
Unlock14.9%5.4%Unlock

Analyst Ratings

22 Buy
1 Hold
1 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.53
(+5.16% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.22%
Dividend Yield
1.16%
Industry Median 1.94%
Annualised payout
0.09
Paid unevenly
5-Years Growth
+8.71%
Growth Streak

Earnings

Latest Release
Aug 18, 2025
EPS / Forecast
0.19 / --
Revenue / Forecast
17.57B / --
EPS Revisions
Last 90 days

1177 Income Statement

People Also Watch

102.70
3690
+0.98%
52.85
1810
-0.47%
19.56
0175
+1.77%
10.07
1093
+6.67%
75.35
1024
-1.44%

FAQ

What Stock Exchange Does Sino Biopharmaceutical Trade On?

Sino Biopharmaceutical is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Sino Biopharmaceutical?

The stock symbol for Sino Biopharmaceutical is "1177."

What Is the Sino Biopharmaceutical Market Cap?

As of today, Sino Biopharmaceutical market cap is 145.58B.

What Is Sino Biopharmaceutical's Earnings Per Share (TTM)?

The Sino Biopharmaceutical EPS (TTM) is 0.22.

When Is the Next Sino Biopharmaceutical Earnings Date?

Sino Biopharmaceutical will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is 1177 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sino Biopharmaceutical Stock Split?

Sino Biopharmaceutical has split 7 times.

How Many Employees Does Sino Biopharmaceutical Have?

Sino Biopharmaceutical has 23056 employees.

What is the current trading status of Sino Biopharmaceutical (1177)?

As of 29 Aug 2025, Sino Biopharmaceutical (1177) is trading at a price of 8.11, with a previous close of 7.69. The stock has fluctuated within a day range of 7.70 to 8.28, while its 52-week range spans from 2.67 to 8.46.

What Is Sino Biopharmaceutical (1177) Price Target According to Analysts?

The average 12-month price target for Sino Biopharmaceutical is HKD8.5284918, with a high estimate of HKD12.25136612 and a low estimate of HKD4.41967213. 22 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +5.16% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.